Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-2618

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-2618). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph showing the percentage of patients with systolic blood pressure (SBP) below 140 mmHg as a function of baseline SBP (mmHg). It compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with Valsartan-HCTZ having the highest percentage across all baseline SBP values.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph comparing the percentage of patients achieving diastolic blood pressure (DBP) below 90 mmHg across different baseline DBP values. It shows four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with the combination therapy group consistently having the highest percentage below the threshold.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph displaying the percentage of patients achieving systolic blood pressure (SBP) under 130 mmHg relative to baseline SBP (140-180 mmHg). It compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, showing effectiveness trends across baseline SBP values.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph comparing the percentage of subjects achieving diastolic blood pressure (DBP) below 80 mmHg against baseline DBP (mmHg) for four treatment groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The graph shows that Valsartan-HCTZ 320/25 mg yields the highest percentage of subjects with DBP under 80 mmHg across baseline values.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, an active ingredient in the drug valsartan and hydrochlorothiazide.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram of the active ingredient hydrochlorothiazide, showing its molecular components and bonds clearly labeled.*

FDA Label Image

Label (Lbl713352618)

Packaging label for Valsartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg strength. The label indicates a package of 30 film-coated tablets, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. The NDC is 71335-2618-1. Storage instructions and dispensing information are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.